Elias Wagner’s group aims at reconciling biological psychiatry with evidence-based medicine. Through multimodal deep phenotyping in multicentric cohorts, they aim at developing a better understanding of disease mechanisms and trajectories in schizophrenia-spectrum disorders (SSD), especially with regard to difficult-to-treat-schizophrenia. His group has a strong interest in cumulative environmental risk factors to unravel heterogenous treatment outcomes in SSD by phenotyping of cerebrospinal fluid.